MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes
Launched by YEDITEPE UNIVERSITY · Oct 11, 2023
Trial Information
Current as of September 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how two specific molecules in our body, called microRNA-1 (miRNA-1) and microRNA-133a (miRNA-133a), change in response to a specific type of exercise known as acute neuromuscular exercise (NME). The study focuses on ultimate frisbee athletes to see if their levels of these microRNAs in saliva change before and after they engage in this exercise. By understanding these changes, researchers hope to learn more about how our bodies respond to physical activity.
To participate, individuals must be between the ages of 65 and 91 and should not currently be dealing with any acute illnesses or have had any injuries that would prevent them from exercising in the last 12 weeks. Participants will take part in the exercise session and provide saliva samples for analysis. It’s important to note that regular use of medications or supplements may exclude someone from joining this study. The trial is currently recruiting, and it offers an opportunity to contribute to understanding how exercise affects our bodies at a cellular level.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Not suffering from an acute illness
- • Not having had an orthopedic injury in the last 12 weeks may prevent them from exercising
- • Volunteering to participate in the study
- Exclusion Criteria:
- • Presence of an acute disease
- • Having an orthopedic injury that may prevent exercise in the last 12 weeks
- • Regular use of medication and/or dietary supplements
- • Presence of a chronic \& systemic disease
- • Not volunteering to participate in the study
About Yeditepe University
Yeditepe University is a distinguished institution dedicated to advancing medical research and education. As a clinical trial sponsor, Yeditepe University leverages its robust academic resources and state-of-the-art facilities to facilitate innovative research initiatives aimed at improving healthcare outcomes. The university is committed to adhering to the highest ethical standards and regulatory requirements in conducting clinical trials, fostering collaborations with healthcare professionals and researchers to explore new therapeutic avenues. Through its comprehensive approach, Yeditepe University strives to contribute significantly to the body of medical knowledge and enhance patient care both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Turkey
Patients applied
Trial Officials
Turgay İsbir, Prof. Dr.
Principal Investigator
Yeditepe University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported